Lupin Limited (LUPIN) shares positive Phase 1 data on LNP8701, a novel SOS1 inhibitor, accepted for ASCO Annual Meeting 2026.
Lupin Limited (LUPIN) receives Establishment Inspection Report (EIR) from U.S. FDA for its Ankleshwar facility, highlighting quality excellence.
Lupin Limited (LUPIN) secures China approval for Oseltamivir Phosphate Oral Suspension, marking its debut in the Chinese market.
Lupin Limited (LUPIN) makes its debut in Dow Jones Best-in-Class Indices 2026, highlighting its strong ESG performance and commitment to sustainability.
Lupin Limited (LUPIN) inaugurates Atharv Ability, a state-of-the-art neuro-rehabilitation center in Delhi, expanding access to advanced care for neurological disorders.
Lupin Limited (LUPIN) announced U.S. FDA approval for Famotidine Injection, expanding its pharmaceutical portfolio with a bioequivalent to Pepcid®.